Polypeptide marker for diagnosis of arteriosclerosis, method for detection of arteriosclerosis by using the maker or the like, and kit for diagnosis of arteriosclerosis
a polypeptide marker and arteriosclerosis technology, applied in the field of polypeptide markers for diagnosis of arteriosclerosis, can solve problems such as unsatisfactory levels, and achieve the effect of high accuracy
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Benefits of technology
Problems solved by technology
Method used
Image
Examples
examples
[0098]Hereunder is a detailed description of the present invention with reference to Examples. However, the present invention is not to be limited by the following description.
production example
Preparation of Samples
[0099](1) The subjects were patients with carotid artery stenoses who had visited our hospital or cooperative institutes. The reference (control) healthy subjects were selected from outpatients so that both groups had matched gender and age (±5 years). When they were visiting as outpatients or hospitalized in the neurosurgery department; 1) their families were explained that this study was to be conducted for research purposes and that cooperation with the study was not compulsory, and informed consents were obtained from them; 2) questions about the family history, the past history, the life style such as drinking and smoking habits, and the work style were asked; 3) blood was collected and separated into serum and corpuscle components and cryopreserved; and furthermore, 4) the clinical seriousness, the therapeutic process, the findings of the blood examination and the like were recorded on the basis of the medical record of the doctor. The patient blood as th...
example 1
Measurement of the Antibody Titer by ELISA Method
[0133]Using the experimental protocol of the Production Example mentioned above, the antibody levels of the thirteen out of the eighteen types of the detected arteriosclerosis diagnostic marker candidates were measured by ELISA, and the presence of the serum antibodies was confirmed. The results of the measurement are shown in Table 2.
TABLE 2Healthy Patient (P)subject (N)standardp valueStandardClone nameAveragedeviation(two-sided)AveragedeviationS19A30.3860.009120.00000.272 0.0624TS27A20.3060.1246 0.00110.229 0.0909S21B10.2060.1271 0.00780.146 0.0779S25E10.3460.3338 0.01450.210 0.1515TS12D20.3180.1959 0.02270.242 0.1019S36C30.0500.0407 0.02810.035 0.0207N48B10.2110.1109 0.04720.165 0.1065S28D10.4930.2525 0.06420.400 0.2251TS27H10.0930.0827 0.06450.067 0.0393PA1050.2560.1414 0.00000.14170.0891PA2020.2890.1546 0.00970.21570.1054PA2130.4400.2052 0.00020.29550.1368PA2340.1500.1001 0.01310.10460.0705
PUM
| Property | Measurement | Unit |
|---|---|---|
| concentration | aaaaa | aaaaa |
| imaging tests | aaaaa | aaaaa |
| MRI | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
Login to View More 
